Who is sponsoring NCT07340424?

NCT07340424 is sponsored by Xiaorong Sun.

What drugs are being tested in NCT07340424?

Interventions in NCT07340424: 225Ac-TR2205 Injection.

What condition does NCT07340424 study?

NCT07340424 studies Advanced Metastatic Triple-negative Breast Cancer (mTNBC).

Is NCT07340424 still recruiting?

NCT07340424 is currently recruiting now. Last updated 6 January 2026.

Last reviewed 2026-01-06 · How we verify

NCT07340424

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Prospective, Open-label, Single-arm, Exploratory Clinical Trial to Evaluate the Safety and Tolerability of 225Ac-TR2205 Injection in Patients With Triple-negative Breast Cancer.

Recruiting now EARLY_PHASE1 Last updated 6 January 2026

What this trial tests

EARLY_PHASE1 trial testing 225Ac-TR2205 Injection in Advanced Metastatic Triple-negative Breast Cancer (mTNBC) in 15 participants. Currently enrolling.

Timeline

22 May 2025

Primary endpoint
1 April 2027

1 May 2029

Quick facts

Lead sponsor	Xiaorong Sun
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	22 May 2025
Primary completion	1 April 2027
Estimated completion	1 May 2029
Sites	1 location across China

Drugs / interventions tested

225Ac-TR2205 Injection — full drug profile →

Conditions studied

Advanced Metastatic Triple-negative Breast Cancer (mTNBC) — all drugs for Advanced Metastatic Triple-negative Breast Cancer (mTNBC) →

Sponsor

Xiaorong Sun — full company profile →

Who can join

18 and older, female only, with Advanced Metastatic Triple-negative Breast Cancer (mTNBC). Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The incidence and severity grades of adverse events (AE), serious adverse events (SAE), and unexpected serious adverse reactions (SUSAR) were evaluated according to the CTCAE 5.0 standard.
Time frame: 8 weeks after the last dose

Sponsor's own description

This study is a prospective, single-center, single-arm, open-label research. It evaluates the safety and tolerability of 225Ac-TR2205 in patients with triple-negative breast cancer (TNBC), and assesses its radiation dosimetry and initial efficacy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xiaorong Sun trials

Trials by the same sponsor.

NCT07135128 — A Clinical Study of [225Ac]Ac-FAPI-XT(XT117) Injection in Patients With Advanced Solid Tumors · Phase 1 · recruiting
NCT07135102 — A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patient · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07340424 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xiaorong Sun
Last refreshed: 6 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07340424.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing